Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
Aug 26, 2026
MRNY ETF Delivers +152% Gain in 30 Days on Moderna (MRNA) Catalyst

MRNY ETF Delivers +152% Gain in 30 Days on Moderna (MRNA) Catalyst

Key Takeaways

  • MRNY gained roughly 152% over the trailing 30 days, with nearly all of that advance occurring in a single session following a landmark clinical catalyst for Moderna (MRNA).
  • The fund is an actively managed single-stock covered-call strategy, meaning its upside participation in MRNA is capped relative to the underlying stock's move.
  • Over the trailing quarter the ETF rose approximately 140%, but virtually the entire gain was concentrated in the final week of the period.
  • The primary driver was positive Phase 3 data for Moderna and Merck's (MRK) personalized mRNA melanoma vaccine, amplified by a heavy short squeeze in MRNA shares.
  • MRNY's income-oriented structure, weekly distributions, and 1.00% expense ratio distinguish it from a direct position in the underlying stock.

Overview of the MRNY ETF and Its Strategy

The YieldMax MRNA Option Income Strategy ETF (MRNY) is an actively managed, non-diversified derivative income fund that seeks current income as its primary objective and capped exposure to the share price of Moderna, Inc. as a secondary objective. Rather than owning MRNA shares directly, the fund uses a synthetic covered-call (call spread) strategy, selling call options on MRNA while holding a collateralized position in cash and U.S. Treasury bills.

The portfolio typically holds roughly 15 to 18 securities, dominated by short-dated U.S. Treasury bills, cash-equivalent vehicles, and MRNA options positions rather than equity holdings. This structure directly shapes performance: MRNY collects option premium and distributes income weekly, but the short call positions limit how much of MRNA's upside the fund can capture during sharp rallies. The fund carries a gross expense ratio of 1.00% and was launched in October 2023. I also checked this using Tickeron’s AI Screener to see how the fund compares to other single-stock option income vehicles.

MRNY's Price Performance Over the Past 30 Days and Quarter

MRNY's recent price action was anything but gradual. The ETF closed near $14.65 roughly 30 days prior and finished the period near $36.97, a gain of approximately 152%. Over the trailing quarter, the fund advanced roughly 140% from a reference level near $15.42.

Critically, the shape of that move matters more than the headline figure. Through July and the first half of August, MRNY drifted lower from the low-$20s toward the mid-$14s, trading in a volatile but broadly range-bound pattern as MRNA shares weakened. The entire repricing occurred on a single day in mid-August, when MRNY surged roughly 169% in one session and subsequently oscillated in a wide $30-to-$42 band as traders reassessed the fund's capped upside.

Key Driver of the Recent 30-Day Rally

The overwhelming driver of MRNY's 30-day surge was a single event in Moderna's oncology pipeline. Moderna and Merck announced that their personalized mRNA cancer vaccine, evaluated in combination with Merck's immunotherapy Keytruda, met its primary endpoints in a Phase 3 trial for high-risk melanoma. The result marked the first late-stage success for an mRNA-based individualized cancer therapy and validated the broader mRNA oncology platform.

MRNA shares soared roughly 177% in one session, climbing from about $63 to approximately $174, before settling back and then rebounding to near $159. The scale of the move was magnified by positioning: short interest in MRNA had been estimated in the low double digits of the company's float, and the scramble to cover bearish bets created a powerful short squeeze. Merck shares also rose by roughly 10% to 12% on the news.

Because MRNY sells call options on MRNA, its roughly 169% single-session gain slightly lagged the underlying stock's move, reflecting the capped participation built into the fund's design. A wave of analyst price-target upgrades across major financial institutions followed the data release, reinforcing the repricing of the underlying equity.

Quarter Performance in Context

For most of the quarter, the environment was far less favorable. Moderna entered the period under pressure from a post-pandemic decline in COVID-19 vaccine revenue and uncertainty around its pipeline, which kept MRNA in a downtrend and left MRNY trading in a choppy $14-to-$21 range. Option premiums and weekly distributions provided income to holders, but the underlying share-price weakness limited capital appreciation.

The quarter's roughly 140% gain is therefore almost entirely attributable to the final-week catalyst rather than a sustained sector rotation. This concentration underscores a defining feature of single-underlying derivative income funds: returns are binary and event-driven, dominated by the fortunes of one issuer rather than by broad market or industry trends.

Outlook for MRNY and What to Monitor

Going forward, MRNY's trajectory will remain tied to Moderna's ability to convert clinical momentum into commercial and regulatory milestones. The full trial dataset, including the recurrence-free survival hazard ratio, is expected to be presented at a major medical conference in late October, and investors will watch whether the detailed results support the initial topline enthusiasm.

Regulatory discussions and a potential approval timeline—management has indicated a possible path toward approval as early as 2027—represent the next key catalysts. Meanwhile, Moderna remains unprofitable, and its share price now reflects substantial optimism, leaving the stock vulnerable to profit-taking and volatility. I’m watching this closely because future gains in MRNA will not translate one-for-one into ETF performance given the capped structure.

Exploring Opportunities with Tickeron’s AI Screener

In my own research, Tickeron’s AI Screener has become a useful tool for scanning single-stock option income ETFs and related biotech names by technical indicators, fundamentals, volatility, and performance metrics. It helps surface candidates that align with specific strategies like income generation or event-driven exposure without requiring hours of manual filtering.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: MRNY

Contributor

My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.


MRNY in upward trend: 10-day moving average moved above 50-day moving average on August 19, 2026

The 10-day moving average for MRNY crossed bullishly above the 50-day moving average on August 19, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 5 of 5 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 17, 2026. You may want to consider a long position or call options on MRNY as a result. In 42 of 49 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.

Following a +5.32% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRNY advanced for three days, in 151 of 165 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

The Aroon Indicator entered an Uptrend today. In 66 of 76 cases where MRNY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.

Bearish Trend Analysis

The 10-day RSI Indicator for MRNY moved out of overbought territory on August 26, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 11 similar instances where the indicator moved out of overbought territory. In 11 of the 11 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Moving Average Convergence Divergence Histogram (MACD) for MRNY turned negative on September 08, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 22 similar instances when the indicator turned negative. In 20 of the 22 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRNY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

MRNY broke above its upper Bollinger Band on August 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Industry description

The investment seeks current income; exposure to the share price of the common stock of Moderna, Inc., subject to a limit on potential investment gains is the secondary consideration. The fund advisor will employ the fund's investment strategy as the fund relates to MRNA regardless of whether there are periods of adverse market, economic, or other conditions and will take temporary defensive positions during such periods. The fund is non-diversified.
View a ticker or compare two or three
MRNY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Category Trading

Profile
Details
Category
Derivative Income
Address
United States
Phone
N/A
Web
N/A
Interact to see
Advertisement
Shares of SailPoint, Inc. (SAIL) are tumbling approximately 12% in premarket trading on March 18, 2026, after the company released its fiscal fourth-quarter and full-year 2026 results before the market opened. While Q4 revenue came in slightly above consensus at $295 million (+23% year-over-year), investors were rattled by disappointing forward guidance for fiscal 2027.
Shares of KC surged approximately +17% in premarket trading on March 18, 2026, from a prior close of $13.12 to approximately $15.35. The primary catalyst is Kingsoft Cloud's release of its unaudited Q4 and full-year 2025 financial results before the U.S. market open, which appear to have significantly exceeded analyst expectations.
AngloGold Ashanti (AU) shares tumbled approximately 7% in premarket trading on March 18, 2026, extending a multi-week downtrend that has erased nearly 20% of the stock's value since late January highs. The primary catalyst driving the decline is persistent investor concern over AngloGold's lowered 2026 production guidance, with the company projecting gold output of 2.80–3.17 million ounces — a roughly 3% decline from its 2025 production of 3.1 million ounces.
AAOI shares surged approximately 10.90% in premarket trading on March 18, 2026, rising from a prior close of $86.33 to $95.74. The primary catalyst is strong positive sentiment generated at OFC 2026 — the Optical Fiber Communications Conference and Exhibition — where Applied Optoelectronics unveiled breakthrough laser and transceiver technology for next-generation AI data center infrastructure.
LITE shares surged approximately +12% in early Wednesday trading on March 18, 2026, with the stock changing hands near $727 compared to a prior session close of $649.56. The primary near-term catalyst is Lumentum's S&P 500 index inclusion, effective March 23, 2026, triggering front-running by institutional investors and mandatory buying by passive index funds.
Shares of New Era Energy & Digital, Inc. (NUAI) are trading down approximately 17% during today's session, with the prior close sitting at $5.56. The decline follows the company's March 17 business update conference call and webcast, held after market hours, during which management discussed the recently filed fiscal year 2025 annual report (Form 10-K).
Shares of Regencell Bioscience Holdings (RGC) are up approximately +16% intraday on March 18, 2026, trading at $26.56 against a prior close of $22.97. No single company-specific press release is driving today's move; the rally is primarily fueled by retail-driven momentum and short squeeze mechanics.
A jump in the Producer Price Index from 0.3% to around 0.7% month‑over‑month signals that wholesale inflation is re‑accelerating, delaying Fed rate‑cut hopes and reviving the “higher for longer” rates narrative.business. Likely winners in this environment include energy and commodity producers (XOM, CVX, TTE, COP), inflation‑resilient financials (JPM, BAC), and real‑asset plays like pipelines and infrastructure, which can pass through higher prices; ETFs like XLE, XOP, XLF, DBA, GLD offer diversified exposure.
BGSI fell more than 11% today, pulling back from recent levels around the high‑$150s as investors reassessed the risk‑reward following the Q4 2025 print and major U.S. expansion plans. Full‑year 2025 sales rose 2.4% to US$3.14 billion, but same‑store sales declined 0.2%, while reported net earnings fell 25% to US$18.4 million due to US$22.6 million in acquisition and transformation costs.
NG shares fell over 11% today, giving back a portion of steep gains that had taken the stock from near US$2.30 a year ago to recent highs around US$14.40 before the latest pullback. The decline follows a cluster of Donlin‑related announcements — including selection of Fluor as Bankable Feasibility Study (BFS) contractor and an infrastructure/energy letter of intent — which, while positive, highlighted the scale, cost and timeline of the project rather than near‑term cash generation.
SA dropped over 9% today, sliding from around US$30–31 toward the high‑US$27 range in morning trading, as recent optimism about a near‑term KSM partnership met renewed focus on execution and valuation risk. Recent analysis has highlighted that Seabridge’s 2026 “report card” allocates 55% of management’s performance weighting to KSM‑related goals, with securing a JV partner given the single largest weight at 30%, underscoring how concentrated the investment thesis has become.
CABO shares fell over 11% today, sliding from the low‑US$110s toward the US$100 area, extending a brutal 12‑month decline of roughly 55% and bringing the stock closer to the bottom of its 52‑week range near US$70. Q4 2025 results showed a 6.1% year‑over‑year revenue drop to US$363.7 million, with residential data revenue down 4.2% and business data off 1.3%; full‑year revenue fell to about US$1.5 billion from US$1.6 billion in 2024.
In a market rattled by geopolitical tension, tariff uncertainty, and Fed rate volatility, one category of stocks continues to electrify traders: penny stocks, microcaps, and small-caps. These sub-$5 shares can surge 50%, 100%, or even 150% in a single session on a news catalyst — but without the right tools, most retail traders get caught on the wrong side. Enter Tickeron's two powerhouse AI robots: the Small-Cap Stocks - AI Trend Trader 60min (FA) and the Penny Stock - MicroCap Signal Bot 60min (FA).
Elite Returns in a Volatile Sector — Both robots delivered annualized returns above 94%, outperforming the vast majority of active semiconductor funds. High Consistency — Win rates of 68–71% mean these robots win more often than they lose — a rare edge in a sector famous for violent swings.
Exceptional Returns: +79.13% annualized return on a starting balance of $8,040.74, demonstrating consistent alpha generation in the comms-tech sector. High Win Rate: 59.43% of trades close in profit, with a Profit Factor of 2.65 — meaning every $1 risked historically returns $2.65.
Tight Risk Management — The 3% TP / 2% SL corridor keeps risk-reward structured and disciplined, cutting losses quickly while locking in gains before reversals. Right Tickers, Right Time — XOM, CVX, and COP are all up roughly 30% year-to-date in 2026, making them among the most high-momentum, liquid energy plays in the market right now.
AngloGold Ashanti (AU) shares are tumbling approximately 11% in premarket trading on March 19, 2026, extending a steep multi-week correction that has now erased more than 35% of the stock's value from its March 2 peak of $129.14. The primary sustained catalyst driving the decline is AngloGold's lowered 2026 production guidance, projecting gold output of 2.80–3.17 million ounces — a mid-point decline versus the company's 2025 output of approximately 3.1 million ounces, and below analyst expectations.
CSIQ shares tumbled approximately 18% in premarket trading on March 19, 2026, following the release of deeply disappointing Q4 2025 earnings before the open. The company reported a net loss of $1.66 per diluted share, far worse than the Wall Street consensus estimate of -$0.98, representing a 69% earnings miss.
YRD shares are tumbling approximately 17% in premarket trading on March 19, 2026, from a prior close of $3.68 to approximately $3.05, following the company's release of Q4 and full-year 2025 financial results before the U.S. market open. Primary catalyst: A dramatic swing to net loss in Q4 2025. Yiren Digital reported a Q4 net loss of RMB 882.2 million (~USD 126.1 million), compared to net income of RMB 331.4 million in Q4 2024 — a more than $250 million deterioration year-over-year.
Shares of MU are down approximately 6.66% in premarket trading on March 19, 2026, sliding from a prior close of $461.73 to around $431.00. Despite a historic earnings beat — fiscal Q2 2026 revenue of $23.86 billion versus the $19.19 billion consensus, and adjusted EPS of $12.20 against an $8.79 estimate — the stock is experiencing a classic "sell the news" reaction.
MRNY ETF Delivers +152% Gain in 30 Days on Moderna (MRNA) Catalyst